Clinical data | |
---|---|
Other names | RDEA-3170; RDEA3170 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H16N2O2S |
Molar mass | 348.42 g·mol−1 |
3D model (JSmol) | |
| |
|
Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.[1][2][3]